Imperial College London Featured PhD Programmes
University College London Featured PhD Programmes
University College London Featured PhD Programmes
Birkbeck, University of London Featured PhD Programmes
Cardiff University Featured PhD Programmes
United Kingdom
Leeds×
10 miles

Cancer / Oncology PhD Projects, Programs & Scholarships in Leeds

We have 40 Cancer / Oncology PhD Projects, Programs & Scholarships in Leeds

  • Cancer / Oncology×
  • United Kingdom×
  • Leeds×
  • clear all
Order by 
Showing 1 to 15 of 40
  Investigating the mechanism of action of dual antiangiogenic/ antineoplastic drugs using organotypic co-culture of fibroblasts and endothelial cells
  Research Group: Institute of Cancer Therapeutics
  Dr J Elies Gomez, Dr K Pors
Applications accepted all year round

Funding Type

PhD Type

An important feature of many types of cancer is the ability to develop abnormal angiogenesis (blood vessel formation); this allows cancer cells to gain access to nutrients and favours metastasis.
  Discovery of chemical and biological tools to probe hypoxic solid tumours
  Research Group: Institute of Cancer Therapeutics
  Dr K Pors, Dr J Elies Gomez
Applications accepted all year round

Funding Type

PhD Type

A major challenge in cancer therapy is to develop therapeutic agents that selectively target tumour cells. One avenue towards the development of more selective cancer therapies is to exploit the unique physiological properties of solid tumours using prodrug approaches.
  Single-molecule fluorescence-activated cell sorting (smFACS): sorting cells molecule by molecule
  Dr A Ponjavic
Application Deadline: 3 January 2020

Funding Type

PhD Type

This project will develop a novel microfluidic device that can characterise and sort cells, with unprecedented (single-molecule) sensitivity.
  Nanopore barcoding for detecting metastases in liquid biopsies
  Dr M Castronovo
Application Deadline: 3 January 2020

Funding Type

PhD Type

Liquid biopsy is set to revolutionized the capacity to detect, assess and monitor the evolution of cancer. This technology has a central role to play in precision medicine and population screening approaches, but remains limited by sensitivity and specificity.
  Epigenetics and Cancer: Determining how Mistakes in V(D)J Recombination Trigger Leukaemias and Lymphomas
  Dr J Boyes
Application Deadline: 25 January 2020

Funding Type

PhD Type

V(D)J recombination is essential to produce an effective adaptive immune system but since the reaction involves the breakage and rejoining of DNA, it is highly dangerous and errors have long been thought to lead to leukaemias and lymphomas.
  MRC DiMeN Doctoral Training Partnership: Developing protein tools to target DNA damage response and repair in cancer cells
  Dr Q. Wu, Dr D Tomlinson
Application Deadline: 6 January 2020

Funding Type

PhD Type

DNA damage response (DDR) and repair play critical roles in influencing the efficiency and sensitivity of many cancer treatments.
  MRC DiMeN Doctoral Training Partnership: Individualised heteroclitic peptide immunotherapies for hepatocellular carcinoma
  Dr A Samson, Dr R Tooze
Application Deadline: 6 January 2020

Funding Type

PhD Type

Background. Hepatocellular carcinoma (HCC) is a cancer of unmet need, with 12% five-year survival across all stages, due to late diagnosis and inadequate non-personalised therapies.
  (MCRC Clinical - Leeds-Manchester) Multi-parametric MRI as a biomarker in CNS radiotherapy trials
  Prof S Short, Dr Stuart Currie, Dr L Murray, Dr M Merchant
Application Deadline: 1 December 2019

Funding Type

PhD Type

This project will apply advanced MR imaging techniques to the problem of risk estimation in patients undergoing complex CNS radiotherapy interventions.
  (MCRC Clinical - Leeds-Manchester) Personalising re-irradiation of locally recurrent prostate cancer directed by MR imaging and hypoxia biomarkers
  Dr Ann Henry, Dr Sarah Brown, Prof D Buckley, Prof A Choudhury
Application Deadline: 1 December 2019

Funding Type

PhD Type

External beam radiotherapy (EBRT) is the most commonly used primary treatment for men with non-metastatic prostate cancer. Outcomes are generally good but 20-50% of patients will develop recurrent disease within 10 years.
  (MCRC Clinical - Leeds-Manchester) Improving the response to neoadjuvant chemotherapy in advanced colon cancer: the relationship between tumour immunology and the microbiome
  Dr N West, Prof Mark Saunders, Prof P Quirke
Application Deadline: 1 December 2019

Funding Type

PhD Type

Colon cancer is a common cause of cancer-related mortality and outcomes are not improving at the same rate as for rectal cancer. High risk patients currently undergo surgery followed by adjuvant chemotherapy.
  MRC DiMeN Doctoral Training Partnership: Dissecting the function of long non-coding RNAs during neuronal differentiation and neuronal diseases
  Dr J Aspden, Dr G Hautbergue, Dr J Fontana
Application Deadline: 6 January 2020

Funding Type

PhD Type

Whilst 85% of our genome is transcribed, only 4% is protein-coding. In fact, many non-coding RNAs exist, some of which are similarly processed to mRNAs, termed long non-coding RNAs (lncRNAs).
  MRC DiMeN Doctoral Training Partnership: Development and application of fast Magnetic Resonance Spectroscopic Imaging methods for neuro-chemical profiling
  Prof J Schneider, Prof S Short
Application Deadline: 6 January 2020

Funding Type

PhD Type

While Magnetic Resonance Imaging is well established to assess anatomy, structure and function in patients and in animal models of human disease alike, (routine) MR Spectroscopy tools to investigate metabolic alterations are far less common.
  MRC DiMeN Doctoral Training Partnership: Role of RNA modifications in virus infection
  Prof A Whitehouse, Prof S Wilson
Application Deadline: 6 January 2020

Funding Type

PhD Type

As an intermediate molecule in the flow of genetic information, RNA offers a critical junction in the cell to regulate many cellular processes that underpin cell biology, development and tissue function.
  MRC DiMeN Doctoral Training Partnership: The impact of virus-specific neutralizing antibodies on oncolytic virus-mediated anti-tumour immune responses
  Dr E Iiett, Dr F Errington-Mais
Application Deadline: 6 January 2020

Funding Type

PhD Type

Initially developed as cytotoxic agents, the anti-tumour properties of oncolytic viruses (OV) are now known to be largely immune-mediated.
  Understanding mechanisms of small-molecule inhibition of the mitochondrial chaperonin HSPD1
  Research Group: BBSRC White Rose DTP
  Dr R.S. Bon, Dr S Muench, Dr H Wurdak
Application Deadline: 6 January 2020

Funding Type

PhD Type

Glioblastoma multiforme (GBM) is the most aggressive form of brain cancer. Treatment options are insufficient, survival rates are low.
Show 10 15 30 per page


FindAPhD. Copyright 2005-2019
All rights reserved.